Obtenez une réponse de cet employeur
Votre CV et votre lettre de motivation, adaptés exactement à ce que l’employeur recherche.
Grünenthal, a global pharmaceutical company, is hiring for a Director of Quality Transformation & Site Excellence in Chile. The role leads quality assessments at manufacturing sites, supports sites during compliance and remediation, and guides regional transformation programs to improve quality systems.
You will mentor site Quality leaders, strengthen quality culture, and drive continuous improvement across multiple sites in a global organization.
Select how often (in days) to receive an alert:
Country: Chile
City: Santiago
Department: Global Operations & Production
Job ID: 45497
Our people in Manufacturing & Global Operations share two priorities: getting things done and making things better. If you're a dynamic person with a positive mindset, you'll fit in well here. It's an international team with a powerful spirit of collaboration. Together, we make sure our products meet the highest standards of quality by constantly searching for ways to improve at every stage of our value chain - from the raw materials we buy through to the logistics network that brings our medicines to patients. Join our team and help us make an even bigger contribution to Grünenthal's future.
What the job looks like
What you'll bring to the table
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We are focussing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved sales of € 1.8 billion.